PRESTIGE CONSUMER HEALTHCARE INC. Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) reported Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities of $428.00 thousand for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-14.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities · last filed 2026-05-14
- PRESTIGE CONSUMER HEALTHCARE INC. unrecognized tax benefits, increase resulting from settlements with taxing authorities for fiscal 2026 was $428.00K, a 9.74% increase from fiscal 2025.
- PRESTIGE CONSUMER HEALTHCARE INC. unrecognized tax benefits, increase resulting from settlements with taxing authorities for fiscal 2025 was $390.00K, a 12.75% decline from fiscal 2024.
- PRESTIGE CONSUMER HEALTHCARE INC. unrecognized tax benefits, increase resulting from settlements with taxing authorities for fiscal 2024 was $447.00K, a 96.05% increase from fiscal 2023.
- PRESTIGE CONSUMER HEALTHCARE INC. unrecognized tax benefits, increase resulting from settlements with taxing authorities for fiscal 2023 was $228.00K, a 94.87% increase from fiscal 2022.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities 12 month |
|---|---|
| 2026-03-31 | $428.00K 10-K · filed 2026-05-14 |
| 2025-03-31 | $390.00K 10-K · filed 2026-05-14 |
| 2024-03-31 | $447.00K 10-K · filed 2026-05-14 |
| 2023-03-31 | $228.00K 10-K · filed 2025-05-09 |
| 2022-03-31 | $117.00K 10-K · filed 2024-05-15 |
| 2021-03-31 | $417.00K 10-K · filed 2023-05-05 |
| 2020-03-31 | $0.00 10-K · filed 2022-05-06 |
| 2019-03-31 | $888.00K 10-K · filed 2020-05-08 |
| 2018-03-31 | $0.00 10-K · filed 2020-05-08 |
| 2017-03-31 | $0.00 10-K · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |